WIA
IMDX

Wealthedge Investment Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Wealthedge Investment Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-73,971
Closed -$226K – 177
2025
Q1 		$226K Buy
73,971
+21,239
+40% +$57.4K 0.1% 147
2024
Q4 		$126K Buy
+52,732
New +$143K 0.06% 157

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wealthedge Investment Advisors's IMDX Position: Q2 2025 in Review

Wealthedge Investment Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q2 2025, closing a stake of 73,971 shares — an estimated $226K sold.

Wealthedge Investment Advisors first reported a position in IMDX in Q4 2024 and held it in 2 quarters. The position peaked at $226K in Q1 2025. 30 funds tracked by Wall St. Rank hold IMDX as of Q2 2025.

  • Wealthedge Investment Advisors reported no remaining Insight Molecular Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Wealthedge Investment Advisors sold 73,971 Insight Molecular Diagnostics shares in Q2 2025, an estimated $226K.
  • Wealthedge Investment Advisors first reported a position in Insight Molecular Diagnostics in Q4 2024 and held it in 2 quarters.
  • Wealthedge Investment Advisors's Insight Molecular Diagnostics position peaked at $226K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2025.

Based on Wealthedge Investment Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.